Demyelination detection in CSF based on electrochemical monitoring of myelin basic protein in comparison between Apta vs. Immuno sensing strategies.

Multiple sclerosis (MS) is a recurrent inflammatory, demyelinating disease of the white matter in central nervous system (CNS). The number of MS patients is increasing, but the diagnostic process is still quite difficult, costly and requires combination of several methods. Myelin basic protein (MBP) makes up to 30 % of the myelin in CNS.

Aptamer-based electrochemical nanobiosensor for research and monitoring of multiple sclerosis in mice models.

Multiple sclerosis (MS) is a severe progressive autoimmune-inflammatory, demyelinating process in the central nervous system (CNS) with heterogeneous neurological symptoms appearing as a consequence of myelin break down. Myelin basic protein (MBP) makes up to 30 % of the CNS myelin [1] and it is known to be released into the cerebrospinal fluid (CSF) as a bioindicator of MS. Autoimmune encephalomyelitis (EAE) is a mice model of MS widely used for research and development of new treatments [2].

Biosensing strategies (approaches) for diagnosis and monitoring of multiple sclerosis.

Multiple sclerosis is a recurrent and progressive inflammatory autoimmune disease causing demyelination in the central nervous system. Nowadays, the number of MS patients is increasing, but the diagnostic process and disease management are still quite difficult and costly and time consuming. The combination of methods used for clinical MS diagnosis mainly relies on MRI, that cannot be used as routine analysis.